Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. by Redman, MW et al.
  
Finasteride Does Not Increase the Risk of High-grade Prostate Cancer: A Bias-
adjusted Modeling Approach 
 
 
Mary W. Redman, Ph.D.1 
Catherine M. Tangen, Dr. PH1 
Phyllis J. Goodman, MS1 
Howard Parnes, M.D.2 
Leslie G. Ford, M.D.2 
M. Scott Lucia, M.D.3 
Charles A. Coltman, Jr, M.D.4  
Ian M. Thompson, M.D.5 
 
 
From; the Fred Hutchinson Cancer Research Center, Seattle, Washington1; the 
Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland2; 
Department of Pathology, The University of Colorado at Denver, Denver, 
Colorado3; the Southwest Oncology Group, San Antonio, Texas4; the Department 
of Urology, The University of Texas Health Science Center at San Antonio, San 
Antonio, Texas5. 
 
Correspondence to: Mary W. Redman, Ph.D. 
   Southwest Oncology Group Statistical Center 
   Fred Hutchinson Cancer Research Center  
   1100 Fairview Ave N., M3-C102  
   206-667-4767  fax 206-667-4408 
   mredman@fhcrc.org 
 
Supported by: CA37429 
 
Keywords:  Prostate Cancer, Cancer Prevention, Finasteride, PSA, Inverse 
probability weighted estimation 
Abstract 
The Prostate Cancer Prevention Trial found that seven years of administration of 
finasteride reduced the risk of prostate cancer by 25% but with an apparent 
increased risk of high grade disease.  Subsequent analyses found that 
finasteride affects cancer detection and improves accuracy of tumor grading at 
biopsy.  We herein estimate the impact of finasteride on the risk of overall and 
high grade prostate cancer, accounting for these biases.  Study endpoints 
(biopsy-proven cancer or a 7-year end-of-study biopsy) were available in 10,182 
of 15,990 subjects assessable for 7-year status and grading information from 500 
subjects diagnosed with cancer who underwent radical prostatectomy.  Prostate 
cancer was observed in 22.9% (4.8% with high grade) in the placebo group 
versus 16.6% (5.8% with high grade) in the finasteride group.  In this bias-
adjusted analysis, the estimated rates are 21.1% (4.2%) and 14.7% (4.8%), 
respectively, a 30% risk reduction in prostate cancer (RR =0.70 (95% confidence 
interval (CI) =0.64-0.76, p<0.0001) and a non-significant 14% increase in high 
grade cancer (RR=1.14 (95% CI = (0.96-1.35), p=0.12) with finasteride. 
Incorporating the prostatectomy data, estimated rates of high grade cancers are 
8.2% (placebo) versus 6.0% (finasteride), a 27% risk reduction (RR = 0.73 (95% 
CI=0.56-0.96, p=0.02)) with finasteride.  While the observed risk of high grade 
disease is greater with finasteride, this appears to be through facilitated 
diagnosis, primarily due to increased biopsy sensitivity.  Men undergoing regular 
prostate cancer screening or who express an interest in cancer prevention 
should be informed of this prevention opportunity. 
Background 
 With one man in seven in the U.S. expected to develop prostate cancer in 
his lifetime due primarily to aggressive screening for the disease and with an 
uncertain impact of screening on morbidity and mortality as well as a human and 
economic cost of treatment, prevention of this common disease is an attractive 
public health strategy.1,2,3  The Prostate Cancer Prevention Trial was initiated in 
1993, testing the hypothesis that finasteride, a selective inhibitor of type 2 five-
alpha reductase, could reduce the risk of prostate cancer detection.  Fifteen 
months prior to planned study completion, the independent Data and Safety 
Monitoring Committee recommended closure due to overwhelming evidence that 
the primary endpoint had been reached: a 25% reduction in risk of prostate 
cancer with finasteride.4  Concurrent with this observation was an apparent 
higher risk of high-grade disease with finasteride.  While the number of high 
grade tumors was considerably smaller than the overall number of tumors 
detected, the increased risk of aggressive disease as well as an editorial 
accompanying the initial publication counseling against its use for prevention, led 
to little use of this agent for cancer prevention.5  In the U.S., early detection and 
treatment remain the primary foci for control of this disease. 
 Since the initial publication of the primary outcome of this study, analyses 
of these contrasting conclusions have continued as well as a widespread debate 
on the utility of finasteride for prostate cancer prevention.  Analyses have 
uncovered a series of effects of finasteride on the detection of prostate cancer 
including improved performance characteristics of for-cause biopsies by (a) 
improved sensitivity of PSA for cancer and high grade cancer detection in 
subjects receiving finasteride, (b) improved sensitivity of digital rectal 
examination for cancer detection in subjects receiving finasteride, and (c) the 
suspected improvement in detection and more accurate grading of high grade 
prostate cancer with prostate biopsy in those subjects receiving finasteride.6,7,8  
While these three detection biases would be expected to lead to ‘over detection’ 
of tumors in study subjects receiving finasteride, there was a counteracting bias 
for greater cancer detection in men in the placebo group who more commonly 
underwent biopsy.   
 To better understand the cumulative effect of these biases on detection of 
prostate cancer in the PCPT, we conducted a set of analyses to explore the 
impact of finasteride on both prostate cancer and high grade disease had all 
study participants submitted to an endpoint biopsy.  These analyses account for 
the selection biases attributable to improved detection of cancer by for-cause 
biopsies with finasteride.  We then conducted an analysis to estimate the true 
prevalence of high grade prostate cancer among men with biopsy-detectable 
prostate cancer, using information from the subset of patients who underwent 
radical prostatectomy.  Radical prostatectomy is a procedure that allows a more 
definitive evaluation of actual tumor grade whereas biopsy has been shown to be 
less reliable and varies in accuracy by finasteride versus placebo.  Finally, we 
examine the impact of imperfect sensitivity of biopsy (to detect prostate cancer) 
on the prevalence within each treatment arm and the overall risk reduction 
associated with finasteride. 
Materials and Methods 
The Prostate Cancer Prevention Trial randomized 18,882 eligible men to 
receive either placebo or finasteride for seven years and to be followed for 7-year 
period prevalence of prostate cancer. Prostate biopsy was performed either due 
to an abnormal digital rectal examination (DRE) or an ‘elevated’ PSA.  An 
elevated PSA was defined as either a value above 4.0 ng/mL in the placebo 
group or an adjusted value in the finasteride group that annually resulted in a 
similar number of biopsy recommendations.9,10  All cancer-free men were 
recommended to undergo an end-of-study prostate biopsy after 7 years of study 
participation, regardless of PSA or DRE findings.  The trial was closed early due 
to overwhelming evidence that finasteride significantly reduced the risk of 
prostate cancer.  At the time of the initial publication of results, a 25% reduction 
in the 7-year period prevalence of prostate cancer attributable to finasteride was 
observed.  These results were based on a dataset frozen in March 2003.  
Subsequent analyses use data through the day of the trial unblinding (June 23, 
2003) yielding additional cases that result in an observed risk reduction of 28%.  
It is this larger dataset we use for the present analyses. 
For the present analyses, a man was defined to have an endpoint if he 
had an interim diagnosis of prostate cancer or if he underwent an end-of-study 
biopsy within 90 days of his 7-year anniversary of his randomization or by June 
23, 2003 (which ever came first).  Due to early closure of the study, 15,990 (85%) 
of the 18,882 men were assessable for the endpoint.  Endpoints were observed 
in 8024 men on the placebo arm and 7966 men on the finasteride arm for a total 
of 10,182 (64%) of the 15,990 men.  A 60% compliance rate for endpoint 
ascertainment was specified in the protocol design assumptions.  For the 
purposes of this paper, we will consider the study’s sample size to be the 15,990 
men who reached their seven year anniversary when the study was reported and 
unblinded.  High grade prostate cancer was defined as a Gleason score of 7 or 
higher.  
A. Predicting prostate cancer prevalence if all subjects had an endpoint 
It is likely that men who did not have an endpoint evaluated have a 
different underlying probability of prostate cancer than those who did have an 
endpoint evaluated.   In order to estimate the cancer prevalence if all subjects 
had an endpoint, a reasonable and often employed assumption is that that there 
are measured study covariates which both explain the differences between men 
with and without endpoints and are related to the risk of prostate cancer. 11  
Under this assumption, for two men with similar covariate values, such as age, 
family history of prostate cancer, and treatment arm assignment, one with an 
endpoint evaluated and one without, the outcome data from the man with the 
evaluated endpoint informs the cancer status for the man without the endpoint 
evaluation.   
An approach which employs this assumption and can be used to estimate 
the prevalence of prostate cancer and high grade disease is Inverse probability 
of censoring weighted (IPCW) estimation. 12  Use of this analysis approach is a 
two-step process; the first step is to estimate the probability of having an 
endpoint evaluated conditional on covariates and the second step is to estimate 
the probability of cancer given the probabilities estimated in the first step.  The 
probability of cancer is estimated by the weighted average of cancers within each 
treatment arm among men with observed endpoint, using the inverse of the 
probabilities from the first step as weights.   
To estimate the probability of having an endpoint evaluated in the first 
step, logistic regression was used.  To model the predicted probabilities, we 
chose study covariates related to both (a) having the study endpoint and (b) 
having a diagnosis of prostate cancer. The baseline covariates that were 
included in these analyses were treatment arm, age, ethnicity/race, prostate-
specific antigen value, and family history of prostate cancer.  Covariates 
measured after randomization that were included in this analysis were interim 
biopsy prompts based on PSA levels or digital rectal examination and ever 
having a negative biopsy result during follow-up and before end of study.  The 
weights were then calculated as the inverse of the fitted (predicted) probabilities 
for men with an endpoint evaluated.  The same weights and approach were used 
to estimate the prevalence of biopsy-detectable high grade cancers in each 
treatment arm. 
B. Predicting high grade prostate cancer by integrating prostatectomy data 
The previous analysis attempts to account for selection bias between the 
treatment arms regarding which participants have a study endpoint evaluated.  In 
particular, it addresses the bias that fewer biopsies were conducted in the 
finasteride group, a bias in favor of finasteride, and the bias associated with 
improved performance of PSA and DRE for indication of for-cause biopsies, a 
bias in favor of placebo.  
The next analysis performed was to account for the effect of finasteride on 
the improved accuracy of prostate biopsy on Gleason grading in men on 
finasteride due to reduced prostate gland volume.  Prostatectomies were known 
to be performed and data were available on 500 of 2017 subjects with cancer.  
This analysis proceeded as the first analysis; first, a logistic regression model 
was used to estimate the probability of prostatectomy conditional on covariates 
for the subset of men diagnosed with prostate cancer.  Next, the prevalence of 
high grade cancer among men with a cancer diagnosis was estimated by the 
weighted proportion of men with high grade disease determined by 
prostatectomy, using a weight that is the inverse of the probability of having had 
both a biopsy and prostatectomy.  The overall prevalence of high grade cancer 
within each treatment arm was then estimated by the product of a) the estimates 
from this analysis (the probability of high grade disease among men with cancer) 
and b) the estimates of prostate cancer prevalence from the first analysis. 
C. Impact of differential biopsy sensitivity on disease prevalence 
The first two analyses addressed biases related to imperfect 
ascertainment of biopsy endpoints on all study participants and differentially 
inaccurate grading of disease severity by biopsy between the treatment arms.  
The first analysis accounted for biases related to missing endpoints to estimate 
the overall prevalence of biopsy-detectable prostate cancer and high grade 
cancer.  The second analysis accounted for biases related to more accurate 
grading of high grade disease with finasteride to estimate the prevalence of true 
high grade cancer (as determined by prostatectomy) among participants with 
biopsy-detectable prostate cancer. 
These analyses employ the assumption that biopsy perfectly detects 
cancer; although there is substantial evidence that 1) biopsy operating 
characteristics are less than perfect and 2) the operating characteristics are 
improved under finasteride.  The final analysis addressed the impact that a 
plausible range of biopsy sensitivity values would have on the true underlying risk 
of prostate cancer and high grade cancer in each arm.  For this analysis we 
assumed that biopsy has perfect specificity (the probability of a negative biopsy 
given no cancer equals 1.0) and perfect positive predictive value (probability of 
cancer given a positive biopsy equal 1.0).13  The probability of true cancer within 
each treatment arm is then estimated by the proportion of observed cancers 
divided by the sensitivity (the probability of a positive biopsy given cancer). 
Biopsy sensitivity to detect cancer was also incorporated into estimates of high 
grade cancer prevalence in the same way.  This employed an additional 
assumption that the true presence of high grade cancer did not depend on 
whether cancer status was observed or not.  This is a somewhat strong 
assumption if in fact the hypothesis that high grade tumors are more prominent is 
true, thereby making cancer more easily detectable on biopsy. If the sensitivity 
was equal across treatments, then the risk ratio would be unaffected by imperfect 
sensitivity.  Alternatively, if the sensitivities are not equal across treatments then 
the true risk ratio is equal to the observed ratio multiplied by the sensitivity of 
biopsy under placebo divided by the sensitivity under finasteride.  Therefore, if 
biopsy sensitivity under finasteride is larger than under placebo, the risk 
reduction is underestimated and if the sensitivity is smaller under finasteride then 
the risk reduction is overestimated.   
All of the analyses presented include weights that are a function of 
measured covariates.  Since the weights are estimated, their inclusion affects the 
variability of overall prevalence and risk estimates.  To account for estimation of 
the weights, 10,000 bootstrap samples of the observed data were constructed.  
The analysis procedures were repeated on each data set and the variance of the 
prevalence estimates was estimated by the variance over all samples.  All 
analyses were done in Splus (Insightful Co., Seattle, WA). 
Results 
Table 1 presents a comparison of the characteristics of men with and 
without a study endpoint.  Characteristics determined to be associated with a 
reduced odds of having an endpoint were randomization to finasteride (OR=0.89) 
and older age (OR=0.98).  Additionally, white race versus other race/ethnicities, 
family history of prostate cancer, interim biopsy prompts based on PSA or DRE 
and a negative interim biopsy were all associated with an increased odds of 
having an endpoint.  While PSA at randomization was marginally associated with 
an increased odds of observed endpoint (OR = 1.14, p < 0.0001) the association 
was no longer significant after adjusting for other covariates (p=0.6).   
 Table 1 Comparison of men with and without endpoint evaluated 
 Endpoint evaluated   
N (%) /mean±std 
No 
N=5,809 
Yes 
N=10,181 OR *(95% CI) p-value* 
Treatment arm     
   Finasteride  3,008 (52%) 4,958 (49%) 0.89 (0.84-0.95) 0.0007 
   Placebo 2,801 (48%) 5,223 (51%) 1.0 (ref.)  
Age at randomization 63.4±5.9 62.9±5.4 0.98 (0.97-0.99) <.0001 
Race     
   White 5,297 (91%) 9,483 (93%) 1.37(1.21-1.55) <.0001 
  Other 512 (9%) 699 (7%) 1.0 (ref.)  
Family history of PCA     
  Yes 782 (13%) 1,698 (17%) 1.23 (1.12-1.35) <.0001 
   No 5,026 (87%) 8,484 (83%) 1.0 (ref.)  
PSA at randomization 1.2±0.7 1.3±0.7 0.99 (0.94-1.04) 0.60 
Prior negative study 
biopsy     
   Yes 463 (8%) 1,349 (13%) 1.60 (1.43-1.80) <.0001 
   No 5,345 (92%) 8,833 (87%) 1.0 (ref.) <.0001 
Biopsy prompt for 
Elevated PSA     
   Yes 69 (1%) 803 (8%) 6.80 (5.32-8.84) <.0001 
   No 5,739 (99%) 9,381 (92%) 1.0 (ref.)  
Biopsy prompt for 
Suspicious DRE     
   Yes 82 (1%) 830 (8%) 5.66 (4.52-7.18) <.0001 
   No 5,726 (99%) 9,352 (92%) 1.0 (ref.)  
*From a multivariable logistic regression model with endpoint evaluated (yes/no) 
as the outcome, adjusting for other factors in Table 1. 
A. Predicting prostate cancer prevalence if all subjects had an endpoint 
Prostate cancer prevalence results from the analyses accounting for non-
random missing biopsy results are presented in Table 2.  The observed rates of 
prostate cancer for the 5223 men in the placebo group and 4959 men in the 
finasteride group with an endpoint were 22.9% and 16.6%, respectively.  Had all 
subjects had a biopsy endpoint, our analysis suggests that the true rate of cancer 
in the 8024 men in the placebo group would have been 21.1% and in the 7966 
men in the finasteride group would have been 14.7%.  As expected, these 
percentages are slightly smaller than what was observed, suggesting that the 
men without the endpoint evaluated were slightly less likely to have prostate 
cancer.  Similarly, while the observed rates of high grade cancer in the placebo 
and finasteride groups were 4.8% and 5.8%, respectively, our analysis estimates 
that the true rates of high grade cancer are 4.2% and 4.8%, respectively.  Of 
interest, the relative risk of prostate cancer is changed minimally from the raw 
data (0.72 vs. 0.70).  The risk of high grade disease associated with finasteride 
after accounting for the missing data decreased from an observed and significant 
21% increased risk to a non-significant 14% increased risk (p=0.12). 
Table 2 Observed and estimated numbers and proportions of prostate cancer 
detected on biopsy 
 Placebo arm N=8024 
Finasteride arm 
N=7966 RR (95% CI) 
Prostate Cancer    
   Estimate of overall prevalence 1693 (21.1%) 1171 (14.7%) 0.70 (0.64-0.76) 
   Observed 1194 (22.9%) 823 (16.6%) 0.72 (0.67-0.79) 
High grade cancer    
   Estimate of overall prevalence 337 (4.2%) 382 (4.8%) 1.14 (0.96-1.35) 
   Observed 252 (4.8%) 288 (5.8%) 1.21 (1.02-1.42) 
 
B. Predicting high grade prostate cancer by integrating prostatectomy data  
The target of this analysis was to estimate the high grade prostate cancer 
status if all biopsy-detected cancers had undergone prostatectomy.  Study 
participants who underwent radical prostatectomy were not a random sample of 
the participants with cancer detected on biopsy.  While treatment group, family 
history, white race, a prior negative study biopsy, and high grade cancer on 
biopsy did not significantly impact on whether a prostatectomy was performed 
and the results were available, younger age, PSA at randomization, biopsy 
prompt by PSA or DRE were positively and significantly associated with having a 
prostatectomy (Table 3).  The majority of biopsies associated with a prompt by 
PSA or DRE (so-called for-cause biopsies) were interim biopsies.  It follows, for 
interim biopsies, there was a longer time observed post-diagnosis to both have a 
prostatectomy and to observe/obtain the prostatectomy results.   
 
 
Table 3 Comparison of men with and without prostatectomy verification of biopsy 
result 
 No prostatectomy N=1517 
Prostatectomy 
N=500 
OR (95% CI)* p-value* 
Treatment arm      
   Finasteride 617 (41%) 206 (41%) 0.97 (0.78-1.21) 0.80 
   Placebo 900 (59%) 294 (59%) 1.0 (ref.)  
Age at randomization 64.6±5.6 61.1±4.2 0.86 (0.84-0.88) <.0001 
Race   1.0 (ref.)  
   White 1,403 (92%) 466 (93%) 1.41 (0.94-2.16) 0.11 
   Other 114 (8%) 34 (7%) 1.0 (ref.)  
Family history of PCA     
   Yes 317 (21%) 117 (23%) 1.02 (0.78-1.31) 0.90 
   No 1,200 (79%) 383 (77%) 1.0 (ref.)  
PSA at randomization 1.6±0.8 1.7±0.7 1.25 (1.07-1.82) 0.006 
Prior negative biopsy   1.0 (ref.)  
   Yes 206 (14%) 67 (13%) 1.05 (0.76-1.44) 0.78 
   No 1,311 (86%) 433 (87%) 1.0 (ref.)  
Biopsy prompt for PSA     
   Yes 350 (23%) 154 (31%) 1.4 (1.07-1.82) 0.01 
   No 1,167 (77%) 346 (69%) 1.0 (ref.)  
Biopsy prompt for DRE     
   Yes 281 (19%) 123 (25%) 1.69 (1.30-2.18) <.0001 
   No 1,236 (81%) 377 (75% 1.0 (ref.)  
High Grade on biopsy     
   Yes 391 (26%) 149 (30%) 1.26 (0.98-1.61) 0.07 
   No 1,126 (74%) 351 (70%) 1.0 (ref.)  
*From a multivariable logistic regression model with prostatectomy (yes/no) as 
the outcome, adjusting for other factors in Table 3. 
High grade cancer prevalence estimates from the analysis which 
incorporated the prostatectomy data are 8.2% in the placebo arm and 6.0% in 
the finasteride arm (see Figure 1).  This results in an estimated number of high 
grade cancers on the finasteride arm to be 478 and 658 on the placebo arm.  
 
The estimated risk reduction with finasteride for Gleason ≤ 6 is 34% (RR (95% 
CI) = 0.66 (0.55-0.80), p=<0.0001) and for Gleason ≥ 7 is 27% (RR (95% CI) 
0.73 (95% CI=0.56-0.96, p=02). 
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Figure 1 Low and high grade cancer status by treatment arm by prostatectomy 
Estimated actual fractions of total subjects with low and high-grade cancer 
 
21.1% 
14.7% 
C. Impact of differential biopsy sensitivity on disease prevalence 
Lastly, we explored what ranges of biopsy sensitivity pairs would need to 
be operational to change the original conclusions of the study with respect to 
high grade disease. From the prostatectomy data, there is evidence that 
finasteride improves the biopsy sensitivity and therefore there is likely greater 
sensitivity of biopsy to detect both cancer and high grade cancer on the 
finasteride arm.  The most likely cause of improved sensitivity of biopsy under 
finasteride is its impact on prostate volume.   
In order to understand how different sensitivities of prostate biopsy for 
detection of prostate cancer and high grade cancer in men receiving finasteride 
or placebo might affect observed rates of disease, we constructed Table 4 using 
data from this last analysis.  We used a range of values of biopsy sensitivity from 
50% to 90%. Prevalence estimates are presented for both high grade disease 
detected by biopsy and as determined by prostatectomy.  The prevalence 
estimates in the first two columns represent the probability of true high grade 
cancer accounting for biopsy sensitivity to detect high grade cancer.  The second 
set of prevalence estimates in the last two columns represent the true high grade 
cancer prevalence accounting for biopsy sensitivity to detect prostate cancer, 
using the prostatectomy data to determine the severity of cancer.  It is likely that 
within a treatment arm, the sensitivity of biopsy to detect high grade cancer 
versus any cancer is not the same. This Table allows an understanding of how 
different pairs of sensitivities of biopsy may affect observed rates of cancer 
detection.  For example, if the sensitivity for high grade prostate cancer in the 
finasteride arm is 80% and 70% for the placebo arm the resulting actual risk of 
high grade disease on biopsy would be 6% and 6%, equal to no difference in 
high grade prostate cancer prevalence on biopsy.  Alternatively,  if the sensitivity 
for prostate cancer ; cancer in the finasteride arm is 80% and 70% for the 
placebo arm taking into account the change in grade anticipated with 
prostatectomy, the risk of high grade disease being truly present would be 7.5% 
and 11.7% respectively, equal to a 36% reduction in risk of high grade cancer 
prevalence with finasteride.  The observed risk ratios estimate the risk reduction 
in biopsy-detectable high grade prostate cancers whereas the sensitivity-
adjusted risk ratios are estimates of the risk reduction in true high grade prostate 
cancer prevalence.   
 
Table 4 High grade cancer prevalence estimates under sensitivity of biopsy to 
detect cancer 
Biopsy 
sensitivity 
High grade on biopsy High grade on prostatectomy 
Placebo Finasteride Placebo Finasteride 
50% 8.4% 9.6% 16.4% 12.0% 
60% 7.0% 8.0% 13.7% 10.0% 
70% 6.0% 6.9% 11.7% 8.6% 
80% 5.2% 6.0% 10.2% 7.5% 
90% 4.7% 5.3% 9.1% 6.7% 
 
Using these data, Figures 2 and 3 present the risk ratios under all pairs of 
sensitivity of prostate biopsy (for finasteride and placebo) to detect high grade 
cancer.  The purpose of Figure 2 is to Beginning with Figure 2, the reader’s 
attention is directed first to the thicker 45○ line which represents the risk ratios 
when the sensitivity is the same under placebo and finasteride.  If biopsy 
sensitivity for cancer detection in both finasteride and placebo-treated subjects is 
presumed equal, from Table 2, one can see that the relative risk for high grade 
disease on biopsy is approximately 1.14, representing the overall 14% higher risk 
of high grade prostate cancer that was estimated if everyone had a biopsy.  The 
values above this line represent risk estimates where biopsy has a greater 
sensitivity for high grade cancer detection if the subject is receiving finasteride 
while the values below the line represent risk estimates where biopsy has a 
greater sensitivity for high grade cancer detection if the subject is receiving 
placebo.  The upper shaded region with risk ratio estimates less than one 
represent values where the 95% confidence interval excludes one where we 
would conclude that finasteride is protective against high grade cancer; 
conversely, the lower shaded region with risk ratios above one represent values 
for which the conclusion would be that finasteride increases the risk of high grade 
cancer.  The white area represents the region where the 95% confidence interval 
around the relative risk estimate includes one and we would conclude there is no 
significant difference in high grade cancer rates between the treatment arms. 
  
 
0.6
0.7
0.8
0.9
1
1.1
1.2
1.4
1.6
1.8
2
2.2
Sensitivity under placebo
S
en
si
tiv
ity
 u
nd
er
 fi
na
st
er
id
e
50% 55% 60% 65% 70% 75% 80% 85% 90% 95%
50%
55%
60%
65%
70%
75%
80%
85%
90%
95%
100%
 
 
Figure 2 Risk ratios for high grade prostate cancer under imperfect sensitivity of 
biopsy to detect high grade cancer with placebo and finasteride 
 
Figure 2 demonstrates that if biopsy sensitivity under finasteride is greater 
than under placebo, the risk of high grade disease on finasteride is either not 
different from or less than the risk of high grade disease on placebo.  More 
specifically, this figure demonstrates that small differences in biopsy sensitivity 
between the treatment arms could explain the observed increased risk of high 
grade cancer with finasteride. 
 
Figure 3 now presents the risk ratio estimates of high grade disease under 
various values of sensitivity of biopsy to detect cancer incorporating the 
prostatectomy data to account for differential misclassification of grade.  As in 
Figure 2, the white area represents the region where the 95% confidence interval 
around the relative risk estimate includes one and the upper shaded region 
represents the values of placebo biopsy sensitivity and finasteride biopsy 
sensitivity where finasteride reduces the risk of high grade cancer.  There are no 
pairs of biopsy sensitivity values between 50-100% where the conclusion would 
be an increased risk of high grade prostate cancer with finasteride.  Of note, a 
conclusion that there is an increased risk of high grade disease with finasteride 
only occurs if biopsy sensitivity were greater than 85% on the placebo arm and 
25 -30% in the finasteride arm, values strongly contraindicated by the observed 
prostatectomy data.  .    
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Figure 3 Risk ratios for sensitivity to biopsy incorporating the prostatectomy data 
 
Discussion 
Although finasteride reduced the risk of prostate cancer by at least 25% in 
the PCPT, the observed higher risk of high-grade tumors led to a general 
dismissal of finasteride for preventing prostate.  Since the original PCPT report in 
2003, investigators have uncovered the following biases in cancer detection 
caused by finasteride: A 'shift' in the receiver operating characteristic curve of 
PSA, enhancing detection of overall and high-grade prostate cancer, an 
increased sensitivity of DRE for cancer detection, and an increased sensitivity of 
biopsy for high-grade cancer detection, all of which were statistically 
significant.6,7,8  These three biases of finasteride were accompanied by a greater 
likelihood of biopsy in the PCPT placebo group 
 The present analyses systematically controlled for these and other factors 
in calculating the true rate of cancer in the two study groups.  Multiple factors, 
including baseline characteristics and characteristics of participants at their 
annual visits, significantly influenced whether a man underwent a biopsy, as the 
PCPT primary endpoint required.  Older subjects and men on finasteride had a 
lower likelihood of biopsy, and race (white), family history of prostate cancer, and 
an interim prostate biopsy recommendation increased biopsy likelihood. 
Our first of two major analyses incorporated all of these covariates and 
showed that the biopsy cancer detection rates in the entire PCPT population 
(15,990 men) would have been similar, albeit slightly lower, than were observed 
in the 10,182 men who actually had an endpoint determined. (Table 2)  Overall 
prostate cancer rates were estimated to be 14.7% (finasteride) and 21.1% 
(placebo) in the entire population and 16.6% (finasteride) and 22.9% (placebo) in 
those where the endpoint was actually evaluated.  Estimates of high-grade 
prostate cancer rates were 4.8% (finasteride) and 4.2% (placebo) in the entire 
population and 5.8% (finasteride) and 4.8% (placebo) in those where the 
endpoint was actually evaluated.  The modeled data substantiate the hypothesis 
that the biasing factor of an increased frequency of biopsy in the placebo group 
had a negligible impact on the outcome comparisons between the placebo and 
finasteride groups but accounting for PSA and DRE biases did result in a high 
grade cancer risk ratio estimate closer to 1.0 as we would expect.  This 
conclusion is important to our second analysis, which comprehensively assessed 
the influence of other factors that can bias biopsy results and thus the cancer 
comparisons between the two study groups. 
Our second analysis controlled for the increased sensitivity of biopsy in 
finasteride-treated men for detecting high-grade prostate cancer among men with 
a cancer diagnosis.  We extended the prostate-cancer grade changes from 
biopsy to radical prostatectomy in the subset of men who had a prostatectomy to 
the entire PCPT population.  The estimated “true” rates of high-grade disease in 
this analysis were 8.2% (placebo) and 6.0% (finasteride), a 27% relative risk 
reduction suggesting that it was highly unlikely that finasteride actually increased 
the risk of high-grade cancer in the PCPT (Fig. 1). 
Limitations of these analyses include imprecision of the 27% reduction in 
high-grade cancer risk because of the relatively small numbers of high-grade 
cancers in the PCPT, assumptions that all study participants could possibly have 
had a prostatectomy upon cancer diagnosis, and assumptions that the weights 
were modeled correctly and included all the relevant information.  However, it 
should be noted that confounding factors would need to be related to both having 
an endpoint and prostate cancer to have an impact.  A major limitation of all 
estimates is inherent with the prostate biopsy itself, which is only a sampling of 
the prostate.  The majority of PCPT men had 6-core biopsies, which would be 
expected to have missed many cancers that would have been detected with the 
current 10-12-core biopsy regimens.  The advantage of the 6-core biopsy, 
however, was in detecting cancers that were more likely to be clinically significant 
(versus detection with 10-12 core biopsies). 
A complex set of factors bear upon the recommendation and decision to 
take finasteride or virtually any other cancer preventive agent.  Important factors 
in the finasteride recommendation/decision include the general burden of 
prostate cancer, clinical significance of the prevented cancers, and drug benefit-
risk ratio.  Consideration of each of these factors tends to throw a favorable light 
on finasteride prevention of prostate cancer.  First, prostate cancer has a 
substantial medical, emotional and financial burden especially with its frequency 
of detection in the atmosphere of a strong emphasis on screening in the U.S.  
Second, the prevented cancers in the PCPT have been evaluated for, and found 
to have, a substantial proportion of clinically significant tumors ([Lucia, CaPR 
2008]).  Even men with less-consequential, low-grade prostate cancers, 
however, frequently seek and receive treatments , which have the consequences 
of high expense, risks of sexual, urinary, and bowel side effects, and an 
emotional toll on patients and families from lifetime follow-up surveillance for 
prostate cancer recurrence.14   
Last and most relevant to the debate about finasteride prevention, is the 
consideration of the agent’s benefit-risk ratio.  Men must weigh the established 
benefits of an observed 25% reduction in prostate cancer (or a 30% actual risk 
reduction as found in this analysis) as well as a decrease in urinary symptoms 
and complications of an enlarged prostate against the potential side effects.  
Although established side effects of finasteride include reduced sexual function, 
the present analyses lead us to conclude that men 55 years or older can remove 
the perceived increased risk of high-grade prostate cancer from their 
consideration of the adverse effects of finasteride.  We found no evidence that 
finasteride induced high-grade disease but that there may have been an actual 
reduction in risk. 
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